Quoin Pharmaceuticals Reports $5.37 Million Net Loss in Q2 2026, Increases R&D Spending

Quoin Pharmaceuticals Ltd. reported a net loss of $5.37 million for the second quarter of 2026, compared to a loss of $3.70 million in the same period of the previous year, reflecting an increase of approximately 45.3%. For the first half of 2026, the company’s net loss reached $10.37 million, up from $7.51 million in the first half of 2025. The increase in losses is attributed to a significant rise in operating expenses, which totaled $5.47 million for the quarter, up from $3.79 million year-over-year. This increase was driven primarily by a 76.8% rise in research and development expenses, which amounted to $3.63 million, as the company intensified its clinical development efforts for its lead product, QRX003.

In terms of financial position, Quoin's total assets decreased to $11.97 million as of June 30, 2026, down from $20.39 million at the end of 2025. The decline in assets was largely due to a reduction in investments, which fell from $14.93 million to $6.95 million. The company’s cash and cash equivalents showed a slight increase, totaling $3.85 million compared to $3.82 million at the end of 2025. However, total liabilities increased to $8.04 million from $7.27 million, primarily due to higher accounts payable and accrued expenses.

Strategically, Quoin Pharmaceuticals has made significant advancements in its clinical programs. The company is currently preparing for pivotal registrational clinical testing of QRX003 for Netherton Syndrome, having opened six clinical sites in the U.S. and additional sites in the UK, Spain, France, and the Netherlands. Furthermore, the FDA granted Fast Track Designation for QRX003, and the company received IND clearance for a Phase 2 study of QRX003 in Peeling Skin Syndrome. Quoin has also established nine commercial partnerships for QRX003 across 61 countries, expanding its potential market reach.

Operationally, Quoin has seen a substantial increase in its employee headcount, reflecting its growth in research and development activities. The company is actively pursuing additional funding to support its operations, as it has incurred net losses since inception and has an accumulated deficit of approximately $81.34 million as of June 30, 2026. The company’s management has expressed substantial doubt about its ability to continue as a going concern without raising additional capital, which may be challenging given current market conditions.

Looking ahead, Quoin Pharmaceuticals aims to continue its focus on the development and commercialization of therapeutic products for rare diseases. The company plans to complete late-stage clinical testing of QRX003 and prepare for potential commercialization in the U.S., Europe, and Japan. However, the timeline for generating revenue remains uncertain, as the company does not expect to achieve profitability until it successfully completes development and secures marketing approval for its product candidates.